uniQure N.V. (QURE): Operating Cash Flow
-$177.96M
Year ended 2025-12-31
-$172.11M
Trailing 12 months to 2026-03-31
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$177.96M | n/m | 2026-03-02, From 2025-01-01 |
| 2024-12-31 | -$182.73M | n/m | 2026-03-02, From 2024-01-01 |
| 2023-12-31 | -$145.93M | n/m | 2026-03-02, From 2023-01-01 |
| 2022-12-31 | -$145.06M | n/m | 2025-02-27, From 2022-01-01 |
| 2021-12-31 | $287.96M | n/m | 2024-02-28, From 2021-01-01 |
| 2020-12-31 | -$134.83M | n/m | 2023-02-27, From 2020-01-01 |
| 2019-12-31 | -$98.68M | n/m | 2022-02-25, From 2019-01-01 |
| 2018-12-31 | -$76.04M | n/m | 2021-03-01, From 2018-01-01 |
| 2017-12-31 | -$64.27M | n/m | 2020-03-02, From 2017-01-01 |
| 2016-12-31 | -$72.19M | n/m | 2019-02-28, From 2016-01-01 |
| 2015-12-31 | $7.47M | n/m | 2018-03-14, From 2015-01-01 |
| 2014-12-31 | -$36.85M | n/a | 2017-03-15, From 2014-01-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| uniQure N.V. (QURE) | 2025-12-31 | -$177.96M | n/m |
| Opus Genetics, Inc. (IRD) | 2025-12-31 | -$35.25M | n/m |
| Arbutus Biopharma Corp (ABUS) | 2025-12-31 | -$39.64M | n/m |
| Pyxis Oncology, Inc. (PYXS) | 2025-12-31 | -$63.50M | n/m |
| CV Sciences, Inc. (CVSI) | 2025-12-31 | -$407.0K | n/m |
| Sol-Gel Technologies Ltd. (SLGL) | 2025-12-31 | $322.0K | n/m |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | 2025-12-31 | -$99.84M | n/m |
| Evommune, Inc. (EVMN) | 2025-12-31 | -$76.44M | n/m |
| Evofem Biosciences, Inc. (EVFM) | 2025-12-31 | -$1.99M | n/m |
Compare QURE, IRD, ABUS, PYXS side by side · Screen every company in Pharmaceutical Preparations ↗